Article Text
Editorial commentary
Interferon β in multiple sclerosis: predicting response at an early stage
Statistics from Altmetric.com
Footnotes
Competing interests: JK has been involved in clinical trials of companies that market drugs for MS (Schering AG, Biogen Idec, Serono, Teva) and with some companies that have development programmes for future drugs in MS. H-PH has received honoraria for consulting and speaking at scientific symposia from Bayer Healthcare, Biogen Idec, BioMS, Merck Serono and Teva-Sanofi, after approval by the CEO of the university hospital and the Rector of Heinrich-Heine-University. Both authors participate in NABINMS, a “specific targeted research project” on neutralising antibodies to interferon-beta in multiple sclerosis, established by the European Commission under its 6th Framework Programme (contract No 018926).